



**Louisiana Department of Health
Health Plan Advisory 16-29
September 30, 2016**

Pharmacy copayment exemptions for preventive medications

To be in compliance with Centers for Medicare and Medicaid Services (CMS) requirements in the Affordable Care Act (ACA) for coverage of preventive medications for eligible recipients in Medicaid the Managed Care Organization (MCO) plans should exempt the following from pharmacy copayments:

- Aspirin 81mg:
 - Women ages 12-79
 - Men ages 45-79
- Vitamin D 400 IU:
 - Women and Men ages 65 and older
- Folic acid 0.4mg and 0.8mg:
 - Women ages 12-54
- Breast cancer preventive medications
 - Tamoxifen
 - Raloxifene
- Tobacco cessation pharmacotherapy
 - Nicotine Transdermal Patch, Inhaler, and Nasal Spray
 - Nicotine Polacrilex Gum and Lozenge
 - Bupropion HCl SR (Zyban® and generic)
 - Varenicline Tartrate (Chantix®)
- Oral fluoride supplementation
 - Sodium fluoride tabs, drops, chewable tabs
 - Recipients 6 months to 5 years old (this should already be copay exempt for recipients < 21 years old)
- Gonorrhea prophylactic medication
 - Erythromycin eye ointment
 - Newborns (this should already be copay exempt for recipients < 21 years old)

The above medications should be payable and available according to the U.S. Preventive Services Task Force (USPSTF) A and B Recommendations. This should be implemented no later than Nov. 1, 2016. We understand some of the copayment exemptions have already been implemented.